What is B. Riley’s Forecast for Altimmune Q1 Earnings?

Altimmune, Inc. (NASDAQ:ALT) – Investment analysts at B. Riley issued their Q1 2025 earnings per share (EPS) estimates for Altimmune in a note issued to investors on Wednesday, November 13th. B. Riley analyst M. Mamtani expects that the company will post earnings per share of ($0.41) for the quarter. B. Riley currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Altimmune’s current full-year earnings is ($0.54) per share. B. Riley also issued estimates for Altimmune’s FY2025 earnings at $0.73 EPS.

ALT has been the subject of a number of other reports. HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Altimmune in a research report on Thursday. UBS Group assumed coverage on Altimmune in a research report on Tuesday. They set a “buy” rating and a $26.00 price objective for the company. Finally, Evercore ISI upgraded Altimmune to a “strong-buy” rating in a research report on Friday, August 9th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.00.

Altimmune Price Performance

Shares of ALT opened at $8.46 on Thursday. Altimmune has a 1 year low of $2.34 and a 1 year high of $14.84. The company has a market capitalization of $600.91 million, a price-to-earnings ratio of -5.45 and a beta of 0.09. The business has a 50-day moving average of $6.99 and a 200-day moving average of $6.90.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.03. Altimmune had a negative return on equity of 52.60% and a negative net margin of 199,076.92%. The firm had revenue of $0.01 million for the quarter. During the same period in the previous year, the business posted ($0.39) earnings per share.

Insiders Place Their Bets

In other Altimmune news, Director David Drutz sold 16,011 shares of the firm’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $6.90, for a total value of $110,475.90. Following the completion of the sale, the director now owns 41,958 shares of the company’s stock, valued at approximately $289,510.20. This trade represents a 27.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 4.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Altimmune

A number of hedge funds have recently added to or reduced their stakes in the company. Bellevue Group AG grew its stake in Altimmune by 43.9% in the third quarter. Bellevue Group AG now owns 863,660 shares of the company’s stock valued at $5,303,000 after acquiring an additional 263,660 shares during the period. BNP Paribas Financial Markets boosted its position in shares of Altimmune by 318.6% during the third quarter. BNP Paribas Financial Markets now owns 42,140 shares of the company’s stock valued at $259,000 after buying an additional 32,072 shares during the last quarter. FMR LLC boosted its position in shares of Altimmune by 546.8% during the third quarter. FMR LLC now owns 51,060 shares of the company’s stock valued at $314,000 after buying an additional 43,166 shares during the last quarter. Summit Financial Wealth Advisors LLC boosted its position in shares of Altimmune by 65.1% during the third quarter. Summit Financial Wealth Advisors LLC now owns 45,918 shares of the company’s stock valued at $282,000 after buying an additional 18,113 shares during the last quarter. Finally, Larson Financial Group LLC purchased a new position in shares of Altimmune during the third quarter valued at approximately $31,000. Institutional investors and hedge funds own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.